Aristea Therapeutics
Aristea Therapeutics is a clinical-stage pharmaceutical company developing novel immunology treatments for orphan diseases. Founded in 2018 and based in San Diego, the pre-revenue private company has raised approximately $117.6 million across three funding rounds.
- Company typePrivate
- Founded2018
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Aristea Therapeutics firmographics
Firmographics- Name
- Aristea Therapeutics
- Legal name
- Aristea Therapeutics, Inc.
- Website
- https://aristeatx.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Aristea Therapeutics is a clinical-stage pharmaceutical company developing novel immunology treatments for orphan diseases. Founded in 2018 and based in San Diego, the pre-revenue private company has raised approximately $117.6 million across three funding rounds.
- Ownership category
- akta.pro rank
Aristea Therapeutics industry classification
Industry- Product category
- Clinical-Stage Orphan Immunology Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Aristea Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aristea Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical product revenue: Pre-revenue clinical-stage company developing drug candidates for immunology treatments targeting orphan diseases. Revenue would be generated through eventual commercialization of approved therapeutics.
Go-to-market motion1 record
Aristea Therapeutics product offering
Product offeringCore offering
Aristea Therapeutics is a clinical-stage drug development company developing novel immunology-based therapeutics for patients with orphan autoimmune diseases. The company uses an immunology-based drug development platform to create treatments addressing rare immunology conditions with significant unmet medical need. The company is pre-revenue and has not publicly named specific product candidates.
Differentiator
Problem solved
Functional benefit
Companies that use Aristea Therapeutics
Customer profileSegments1 record
Ideal customer profiles2 records
Aristea Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Aristea Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Aristea Therapeutics competitors and assessment
Company assessmentDirect peers
- Madrigal Pharmaceuticals: Clinical-stage pharmaceutical company focused on rare diseases, with a lead asset approved for a rare liver condition. Direct comparator on rare-disease commercial strategy and clinical-stage positioning.
- ChemoCentryx: Clinical-stage company developing therapeutics for rare autoimmune and inflammatory diseases (acquired by Amgen in 2022 for $3.7B). Direct comparability to Aristea given shared focus on rare immunology indications and orphan disease commercial models.
- Arena Pharmaceuticals: Clinical-stage immunology company (acquired by Pfizer in 2022 for ~$6.7B) that developed therapies for orphan immunology indications including eosinophilic esophagitis. Arena was also a direct investor in Aristea's Series B, reflecting strategic adjacency in immunology pipeline development.
- Pliant Therapeutics: Clinical-stage biotech developing therapies for fibrotic diseases, with significant orphan/rare disease focus. Comparable stage and orphan-disease commercial orientation to Aristea.
- Alpine Immune Sciences: Clinical-stage immunology company developing protein-based therapies for autoimmune and inflammatory diseases (acquired by Vertex in 2024 for ~$4.9B). Direct overlap with Aristea in rare immunology pipeline development.
- Kezar Life Sciences: Clinical-stage immunology company developing small molecule therapies for autoimmune diseases and severe inflammation. Comparable in stage, therapeutic area, and orphan/rare disease orientation.
Emerging players
- Arcturus Therapeutics: Clinical-stage company with rare disease programs including rare metabolic and immunology-adjacent conditions. Partial overlap as a mid-stage rare disease developer comparable in stage to Aristea.
Broad incumbents
- BioMarin Pharmaceutical: Commercial-stage rare disease biopharma with multiple approved orphan therapeutics. Comparable focus area and serves as a benchmark for the long-term commercial trajectory Aristea could pursue.
- Ultragenyx Pharmaceutical: Commercial-stage biopharma focused exclusively on rare and ultra-rare diseases. Represents the scaled rare-disease platform archetype and is a relevant reference point for Aristea's orphan-focused strategy.
- Horizon Therapeutics: Established rare and orphan disease-focused biopharma (acquired by Amgen in 2023 for $28B) with multiple approved immunology assets. Representative of the mature, scaled version of Aristea's orphan-immunology thesis and a likely acquirer profile.
Market position
Customer concentration
Aristea Therapeutics social profiles
Digital presenceAristea Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aristea Therapeutics leadership team
Management profileNumber of profiles
Aristea Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aristea Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aristea Therapeutics
What does Aristea Therapeutics do?
Aristea Therapeutics is a clinical-stage drug development company developing novel immunology-based therapeutics for patients with orphan autoimmune diseases. The company uses an immunology-based drug development platform to create treatments addressing rare immunology conditions with significant unmet medical need. The company is pre-revenue and has not publicly named specific product candidates.
Is Aristea Therapeutics a public or private company?
Aristea Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aristea Therapeutics founded?
Aristea Therapeutics was founded in 2018. It employs 1 to 10 people.
Where is Aristea Therapeutics based?
Aristea Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Aristea Therapeutics make money?
One revenue line is on record: pharmaceutical product revenue.
Who are Aristea Therapeutics's main competitors?
Direct peers on record are Madrigal Pharmaceuticals, ChemoCentryx, Arena Pharmaceuticals, Pliant Therapeutics, Alpine Immune Sciences and Kezar Life Sciences. Arcturus Therapeutics is listed as an emerging player. Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Horizon Therapeutics.
Does Aristea Therapeutics have an API?
No public API is recorded for Aristea Therapeutics.
What industry is Aristea Therapeutics in?
Aristea Therapeutics's product category is Clinical-Stage Orphan Immunology Therapeutics. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.